Ulcerative colitis induced by obinutuzumab in a patient treated for a folicular lymphoma.

López-Mourelle, Ana; Rubiera, Miriam; Lamas-Álvarez, Sara; Argüelles-Estrada, Pablo; de Francisco, Ruth; Pérez-Martínez, Isabel; Castaño-García, Andrés; Riestra, Sabino

López-Mourelle, Ana; Rubiera, Miriam; Lamas-Álvarez, Sara; Argüelles-Estrada, Pablo; de Francisco, Ruth; Pérez-Martínez, Isabel; Castaño-García, Andrés; Riestra, Sabino.

Afiliação

López-Mourelle A; Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, España.
Rubiera M; Pathology, Hospital Universitario Central de Asturias.
Lamas-Álvarez S; Gastroenterology and Hepatology, Hospital Universitario Central de Asturias.
Argüelles-Estrada P; Gastroenterology and Hepatology, Hospital Universitario Central de Asturias.
de Francisco R; Gastroenterology and Hepatology, Hospital Universitario Central de Asturias.
Pérez-Martínez I; Gastroenterology and Hepatology, Hospital Universitario Central de Asturias.
Castaño-García A; Gastroenterology and Hepatology, Hospital Universitario Central de Asturias.
Riestra S; Gastroenterology and Hepatology, Hospital Universitario Central de Asturias.

Rev Esp Enferm Dig ; 2023 Oct 26.

Article em En | MEDLINE | ID: mdl-37882200

ABSTRACT

ABSTRACT

An increasing use of immunomodulatory drugs has led to a corresponding increase in treatment-related pathologies such as inflammatory bowel disease. Here, we present a case of ulcerative colitis due to Obinutuzumab, an antiCD20 monoclonal approved for the treatment of Non-Hodgkin lymphomas.

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Rev Esp Enferm Dig Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article